26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Most Recent Episode Manic)
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 01 Oct 2019 Planned End Date changed from 4 Apr 2021 to 7 Jul 2021.
- 01 Oct 2019 Planned primary completion date changed from 4 Apr 2021 to 7 Jul 2021.
- 26 Apr 2019 Planned End Date changed from 17 Sep 2020 to 4 Apr 2021.